Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

risperidone

- PMLiVE

Johnson & Johnson’s IL-23 inhibitor Tremfya granted FDA approval for ulcerative colitis

The inflammatory bowel disease is estimated to affect more than one million people in the US

- PMLiVE

J&J presents positive late-stage results for Rybrevant/Lazcluze combination in NSCLC

The chemotherapy-free regimen was approved in the US last month for advanced lung cancer patients

- PMLiVE

Johnson & Johnson’s Rybrevant combination approved by EC for expanded lung cancer use

Approximately 484,306 cases of lung cancer were diagnosed in Europe in 2022

- PMLiVE

J&J’s pan-FGFR kinase inhibitor Balversa approved by EC to treat bladder cancer

Up to 20% of patients with metastatic urothelial carcinoma have FGFR alterations

- PMLiVE

J&J to expand cardiovascular capabilities with V-Wave acquisition worth up to $1.7bn

The company’s medtech division will gain access to a cardiovascular implant device for heart failure

- PMLiVE

J&J’s Rybrevant/Lazcluze combination approved by FDA as first-line lung cancer treatment

Non-small cell lung cancer accounts for up to 85% of all lung cancer cases

- PMLiVE

Johnson & Johnson’s Darzalex Faspro regimen approved by FDA for multiple myeloma

More than 35,000 new cases of the blood cancer are expected to be diagnosed in the US this year

- PMLiVE

Johnson & Johnson’s Yuvanci recommended by CHMP to treat pulmonary arterial hypertension

The rare form of pulmonary hypertension affects around 30,000 people in the EU

- PMLiVE

Johnson & Johnson’s Rybrevant recommended by CHMP for pre-treated advanced NSCLC

Non-small lung cancer accounts for up to 85% of all lung cancer cases

- PMLiVE

J&J’s Tecvayli recommended by NICE to treat relapsed and refractory multiple myeloma

Approximately 5,900 new cases of the blood cancer are diagnosed every year in the UK

- PMLiVE

J&J and Legend share positive late-stage results for Carvykti in multiple myeloma

More than 35,000 new cases of the blood cancer are expected to be diagnosed in the US this year

- PMLiVE

J&J’s multidrug-resistant TB treatment Sirturo granted full EC and FDA approvals

An estimated 410,000 people globally developed multidrug- or rifampicin-resistant TB in 2022

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links